Spasticity: Revisiting the role and the individual value of several pharmacological treatments

NeuroRehabilitation

Volumn 27, Issue 2, 2010, Pages 193-200

  Lapeyre, Eric ^a   Kuks, Jan B M ^b   Meijler, Willem J ^c  

^a Hôpital de Percy   (France)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Neurology and Clinical Pharmacology   (Netherlands)

Author keywords

pharmacology; review; Spasticity; treatments

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A; CANNABIS; CLONAZEPAM; DANTROLENE; DIAZEPAM; GABAPENTIN; TIZANIDINE;

ATAXIA; BRADYCARDIA; CLINICAL TRIAL; CONFUSION; CONVULSION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HALLUCINATION; HEADACHE; HUMAN; HYPOTENSION; LIVER TOXICITY; MUSCLE HYPOTONIA; NAUSEA; NYSTAGMUS; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SPASTICITY; SYNCOPE; TREMOR; VERTIGO; VOMITING; WEAKNESS; XEROSTOMIA;

AMINES; BACLOFEN; BOTULINUM TOXINS; CALCIUM CHANNEL BLOCKERS; CLONIDINE; CYCLOHEXANECARBOXYLIC ACIDS; DANTROLENE; DIAZEPAM; GAMMA-AMINOBUTYRIC ACID; HUMANS; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; RECOVERY OF FUNCTION; TREATMENT OUTCOME;

EID: 77957287231     PISSN: 10538135     EISSN: None     Source Type: Journal    
DOI: 10.3233/NRE-2010-0596     Document Type: Review

References (50)

1. S.K. Aggarwal, G.T. Carter, M.D. Sullivan, C. ZumBrunnen, R. Morrill and J.D. Mayer, Medicinal use of cannabis in the United States: Historical perspectives, current trends, and future directions, Journal of Opioid Management 5 (2009), 153-168.
2. S. Beard, A. Hunn and J.Wight, Treatments for spasticity and pain inmultiple sclerosis: a systematic review, Health Technol Assess 7 (2003), iii, ixx, 1-111. (Pubitemid 38028447)
3. F. BieringSørensen, J. Nielsen and K. Klinge, Spasticityassessment: a review, Spinal Cord 44 (2006), 708-722.
4. T.J. Bovend Eerdt, M. Newman, K. Barker, H. Dawes, C. Minelli andD.T.Wade, The Effects of Stretching in Spasticity: A Systematic Review, Arch Phys Med Rehabil 89 (2008), 1395-1404. (Pubitemid 351884984)
5. C.H. Chan, Dantrolene sodium and hepatic injury, Neurology 40 (1990), 1427-1432.
6. R. Chou, K. Peterson and M. Helfand, Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review, J Pain Symptom Manage 28 (2004), 140-175. (Pubitemid 38970077)
7. C. Collin, P. Davies, I.K.Mutiboko and S. Ratcliffe, Randomized controlled trial of cannabisbased medicine in spasticity caused by multiple sclerosis, J Neurol 14 (2007), 290-296. (Pubitemid 46384865)
8. A. Dario and G. Tomei, A benefitrisk assessment of baclofen in severe spinal spasticity, Drug Saf 27 (2004), 799-818. (Pubitemid 39243562)
9. E.M.De Graff,M.Oosterveld, T. Tjabbes and B.H. Stricker, A case of tizanidineinduced hepatic injury, J Hepatol 25 (1996), 772-773.
10. J.A. Durham, A.J. Gandolfi and J.B. Bentley, Hepatotoxicological evaluation of dantrolene sodium, Drug Chem Toxicol 7 (1984), 3-40.
11. A. Formica, K. Verger, J.M. Sol and C. Morralla, Gabapentin for spasticity: a randomized, double blind, placebocontrolled trial, Med Clin (Barc) 124 (2005), 81-85.
12. M. Gruenthal, M. Mueller, W.L. Olson, M.M. Priebe, A.M. Sherwood and Olson, Gabapentin for the treatment of spasticity in patients with spinal cord injury, Spinal Cord 35 (1997), 686-689. (Pubitemid 27468690)
13. R. Herman, W. Freedman and N. Mayer, Neurophysiologic mechanism of hemiplegic and paraplegic spasticity: implications for therapy, Arch Phys Med Rehab 55 (1974), 338-343.
14. C.B. Ivanhoe and T.A. Reistetter, Spasticity: the misunderstood part of the upper motor neuron syndrome, Am J Phys Med Rehabil 83 (Suppl) (2004), S3-S9. (Pubitemid 39281263)
15. L. Kamen, H. Henney and J. Runyan, A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury, Curr Med Res 24 (2008), 425-439. (Pubitemid 351294392)
16. U. Kischka U, Neurological rehabilitation and management of spasticity, Medicine 3612, 2008, 616-619.
17. K. Kolaski and L.R. Logan, A review of the complications of intrathecal baclofen in patients with cerebral palsy, NeuroRehabilitation 22 (2007), 383-395
18. S. Koussoulakos, Botulinum neurotoxin: the ugly duckling, Eur Neurol 61 (2009), 331-342.
19. T. Krause, M.U. Gerbershagen, M. Fiege, R. Weisshorn and F. Wappler, Dantrolene: a review of its pharmacology, therapeutic use and new developments, Anaesthesia 59 (2004), 1139-1140. (Pubitemid 38489297)
20. S.E. Lakhan and M. Rowland, Whole plant cannabis extracts in the treatment of spasticity inmultiple sclerosis: a systematic review, BMC Neurology 9 (59) (2009), 10.1.1186/14712377959.
21. Y. Lapierre, R. Elie and L. Tetreault, Diazepam and benzoctamine: effects on certain objective parameters of muscular spasticity, Current Ther Res 8 (1973), 521-533.
22. J.H. Lee, I.Y. Sung, J.Y. Yoo, E.H. Park and S.R. Park, Effects of different dilutions of botulinum toxin type A treatment for children with cerebral palsy with spastic ankle plantarflexor: a randomised controlled trial, J Rehabil Med 41 (2009), 740-745.
23. Y. Li, X. Li, P.J. Harvey and D.J. Bennett, Effects of baclofen on spinal reflexes and persistent inward currents in motoneurons of chronic spinal rats with spasticity, J Neurophysiol 92 (2004), 2694-2703. (Pubitemid 40340482)
24. M.L. Mathre, Cannabis in Medical Practice, A Legal, Historical, Pharmacological Overview of the Therapeutic use of Marijuana, McFarland & Comp, 1997.
25. P. McCrory, L. TurnerStokes, I.J. Baguley, S. De Graff, P. Katrak, J. Sandanam, L. Davies, M. Munns and A. Hughes, Botulinum toxin A for treatment of upper limb spasticity following stroke: a multicentre randomized placebocontrolled study of the effects on quality of life and other personcentred outcomes, J Rehabil Med 41 (2009), 536-544.
26. W.J. Meijler and S. den Breejen, Safety update of dantrolene sodium, a muscle relaxant for the treatment of spasticity, Eur J of Neurol 16 (Suppl 3) (2009), 243.
27. W.J. Meyler, H. Bakker, J.J. Kok, S. Agoston and H. Wesseling, The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration, J Neurol Neurosurg Psychiatry 44 (1981), 334-339. (Pubitemid 11070508)
28. S. Muehlschlegel and J.R. Sims, Dantrolene: Mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit, Neurocrit Care 10 (2009), 103-115.
29. P.W. Nance and J.M. Meythaler, Spasticity Management, PhysicalMedicine and Rehabilitation, Saunders Elsevier, (3th Ed), (2007), 651-662.
30. E. Odding, M.E. Roebroeck and H.J. Stam, The epidemiology of cerebral palsy: incidence, impairment and risk factors, Disabil Rehabil 28 (2006), 183-191. (Pubitemid 43250489)
31. C.A. Olesch, S. Greaves, C. Imms, S.M. Reid and H.K. Graham, Repeat botulinum toxinA injections in the upper limb of children with hemiplegia: a randomized controlled trial, Dev Med Child Neurol 3 (2009), (Epub ahead of print).
32. G. Pryce and D. Baker, Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, Cannabinoid Receptors, Brit J Pharmacol 150 (2007), 519-525. (Pubitemid 46280648)
33. F.J. Richardson and S. Agoston, Neuroblocking agents and skeletal muscle relaxants, in: Meyler s Side Effects of Drugs, M.N.G. Dukes, ed., Elsevier, Amsterdam, 1992: p. 282.
34. M.A. Rizzo, O.C. Hadjimichael, J. Preiningerova and T.L. Vollmer, Prevalence and treatment of spasticity reported by multiple sclerosis patients, Mult Scler 5 (2004), 589-595. (Pubitemid 39207235)
35. N. Rustemovic, M. Huic and M. Opacic, Tizanidineinduced acute toxic hepatitis: case report, Pharmaca 32 (1994), 457-461.
36. D.T. Shakespeare, M. Boggild and C. Young, Antispasticity agents for multiple sclerosis, Cochrane Database Syst Rev 4 (2003), CD001332.
37. G. Sheean, Botulinum toxin treatment of adult spasticity: a benefit risk assessment, Drug Saf 29 (2006), 31-48. (Pubitemid 43213894)
38. G. Sheean, Pathophysiology of spasticity, Eur J Neurol 9(Suppl 1) (2002), 3-9.
39. C. Sköld, R. Levi and A. Seiger, Spasticity after traumatic spinal cord injury: nature, severity and location, Arch Phys Med Rehabil 80 (1999), 1548-1557. (Pubitemid 30033310)
40. M.H. Soriani and C. Desnuelle, Epidemiology of amyotrophic lateral sclerosis, Rev Neurol (Paris) 165 (2009), 627-640.
41. P. Steinbok, Selective dorsal rhizotomy for spastic cerebral palsy: a review, Childs Nerv Syst 23 (2007), 981-990.
42. M. Taricco, R. Adone, C. Pagliacci and E. Telaro, Pharmacological interventions for spasticity following spinal cord injury, Cochrane Database Syst Rev 2 (2000), CD001131.
43. R. Utili, J.K. Boitnott and H.J. Zimmerman, Dantroleneassociated hepatic injury. Incidence and character, Gastroenterology 72 (1977), 610-616. (Pubitemid 8097598)
44. A.J. Wagstaff and H.M. Bryson, Tizanidine: a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders, Drugs 53 (1997), 435-452.
45. A.B. Ward, Spasticity treatment with botulin toxins, J Neural Transm 115 (2008), 607-616.
46. C.L. Watkins, M.J. Leathley, J.M. Gregson, A.P. Moore, T.L. Smith and A.K. Sharma, Prevalence of spasticity post stroke, Clin Rehabil 5 (2002), 515-522.
47. L.C.Wijesekera and P.N. Leigh, Amyotrophic lateral sclerosis, Orphanet J Rare Dis 4 (2009), 3.
48. J. Wissel, A.B. Ward, P. Erztgaard, D. Bensmail, M.J. Hecht, T.M. Lejeune and P. Schnider, European consensus table on the use of botulinum toxin type A in adult spasticity, J Rehabil Med 41 (2009), 13-25.
49. www.wemove.org .
50. F. Zhao, P. Li, S.R. Chen, C.F. Louis and B.R. ruen, Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity, J Biol Chem 267 (2001), 13810-13816. (Pubitemid 37391758)